Archives of Drug Information

Edited by:
C. Michael Stein

Why should you publish your drug research in Archives of Drug Information?

• Your research will be peer-reviewed
• Publishing time is as fast as 35 days
• Submitting your paper is easy online

Go to http://mc.manuscriptcentral.com/ADI today!

Archives of Drug Information (ADI) provides a forum for advancing the innovative work of drug discovery, and reflects the needs of the pharmaceutical and medical community - all those seeking a home for articles on inconclusive and/or negative clinical trials, early drug development, routine drug-drug interactions, pharmacokinetic studies and other low-profile areas that are traditionally overlooked. Results of clinical trials and drug studies are also featured.

ADI is an open access, freely available peer-reviewed journal dedicated to creating the transparency requested by societies, health care professionals, industry, patients, government and the media to disclose clinical trial information. A broad range of research content including cellular, animal and human studies will be prominently featured.

TopNews and Announcements

Now Accepting Papers!
Go to http://mc.manuscriptcentral.com/ADI to submit your drug trial results today!

Unlike many other medical journals, ADI welcomes articles in the following areas, including repeated or low-profile studies:

• Inconclusive, negative and null studies
• Early drug development
• Routine PK or interaction studies
• Dose-finding studies and animal toxicity studies
• Clinical studies

NIH Public Access Mandate
For those interested in the Wiley-Blackwell policy on the NIH Public Access Mandate, please visit our policy statement.

TopEndorsements

"The Archives of Drug Information will provide a valuable new source of information that is often not available in a timely and unbiased fashion."
Raymond L. Woosley, MD, PhD

"This is a timely and important endeavor. Considering the increasing concerns about adverse drug reactions, both during development and widespread clinical use, this journal will serve a unique function of placing in the public domain, peer-reviewed high quality information about drugs in development viewed by traditional journals as low priority."
Richard B. Kim, MD
Chair, Division of Clinical Pharmacology
The University of Western Ontario

'This journal provides the first real opportunity to publish critical information on pre-clinical and clinical drug studies that here-to-fore would dnot have appeared in a peer reviewed publication.'
Jason D. Morrow, MD
Chief, Division of Clinical Pharmacology
Vanderbilt University School of Medicine